Receive the latest updates from Matrix Medical in real time to understand product information.

The 10th Vascular Innovation Conference (VINNOVA) will be grandly held in Beijing from May 9th to 11th, 2025. Hangzhou Matrix Medical Technology Co., Ltd. (hereinafter referred to as "Matrix Medical"), as a representative enterprise in the field of vascular intervention devices in China, was invited to attend the conference and unveiled its soon to be launched hemostatic device.

Authoritative recognition: Matrix Medical appears on the academic stage 

The 10th Vascular Innovation Conference (VINNOVA) is jointly organized by the Vascular Medicine Professional Committee of the Chinese Research Hospital Association, the Vascular Device Branch of the China Medical Device Industry Association, the Beijing Borui Vascular Health Public Welfare Foundation, AVS Brief Report and Innovation Magazine, and the China Medical Innovation Alliance. This forum brings together clinical experts, research institutions, and innovative enterprises from the industry. The invitation to participate in Juzheng Medical reflects the industry's full recognition of our technological strength and innovation capabilities.

New product launch: Three core advantages of hemostatic devices for occlusion

Matrix Medical always adheres to the guidance of clinical needs and is committed to solving practical problems in the treatment of vascular diseases through innovative technologies. During the forum, Liu Yang, the R&D Director of Matrix Medical, delivered a keynote speech titled "Application of Collagen Materials in Blocking Hemostasis Products", fully disclosing the innovative product independently developed by the company - Blocking Hemostasis Device. This product innovatively uses collagen material, significantly improving the success rate and effectiveness of hemostasis, and accurately filling the current demand gap in the field of puncture site hemostasis. Its advantages are as follows:

1.Innovative design of "balloon assisted collagen sponge"

Provide more precise hemostatic solutions that meet clinical needs.

2.Realize precise occlusion of 8F large caliber extracorporeal vessels

Breaking through the limitations of traditional hemostatic instruments in controlling large caliber blood vessels, providing reliable options for complex clinical cases.

3.Addressing the pain points of residual risks associated with traditional hemostatic devices

Reduce the incidence of postoperative complications and improve the clinical prognosis of patients.

Liu Yang emphasized in his speech: "Thank you to VINNOVA conference for giving us the opportunity to have in-depth exchanges with clinical experts and research institutes, and to showcase our latest research and development achievements. Our hemostatic device is expected to obtain relevant certificates by mid-2025, and its launch will provide clinical doctors with a safer and more effective treatment option. In the future, we will continue to focus on the field of vascular disease treatment, meet clinical needs, launch more breakthrough products, and bring new hope to vascular disease patients

The road to innovation is long and arduous, only through hard work can we achieve great success! From academic stage to product implementation, Matrix Medical is driving industry transformation with innovative steps. Thank you to every clinical expert and partner for their support. We will continue to use technology to safeguard life and health!

In front of the Juzheng Medical booth, staff will answer questions and clarify doubts for everyone

1、Introduction to VINNOVA Vascular Innovation Conference

As an important communication platform in the field of vascular diseases, the forum has attracted outstanding individuals from various industries such as hospitals, research institutes, business, government, universities, and investment institutions, and the participation scale has been increasing year by year. The Vascular Innovation Conference focuses on hot topics in various fields such as peripheral blood vessels, cerebral blood vessels, and cardiovascular diseases, and conducts in-depth discussions through diverse forms such as keynote speeches, successful case sharing, product roadshows, and innovative training and coaching. The conference aims to stimulate innovative vitality in cross disciplinary cooperation, provide exploration directions for industry pioneers, and jointly promote high-quality development in the field of vascular disease diagnosis and treatment.

2、Liu Yang's Personal Profile

Dr. Liu Yang is an associate researcher and master's supervisor at the School of Medicine and Health Engineering and the Institute of Biomedical Engineering and Health Sciences at Changzhou University. He also serves as the research and development director of Juzheng Medical.

Dr. Liu Yang focuses on cutting-edge fields such as biomedical materials, surface modification of polymer materials, implantable/interventional medical devices, and antibacterial functional materials. He has led multiple national and provincial research projects, achieved fruitful results, published multiple high-quality academic papers, and applied for multiple invention patents. As the R&D Director of Matrix Medical, Dr. Liu Yang has led his team to achieve significant achievements in the field of vascular intervention therapy.

Dr. Liu Yang's dual identity in academia and industry enables him to quickly transform cutting-edge scientific research achievements into practical applications, promote technological innovation in the medical device industry, and provide strong technical support and innovation momentum for the development of the medical device industry.